(AMN) AMN Healthcare - Overview
Stock: Nurse, Allied, Physician, Leadership, Technology
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 54.0% |
| Relative Tail Risk | -12.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.24 |
| Alpha | -37.60 |
| Character TTM | |
|---|---|
| Beta | 0.848 |
| Beta Downside | 1.299 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.48% |
| CAGR/Max DD | -0.46 |
Description: AMN AMN Healthcare December 25, 2025
AMN Healthcare Services, Inc. (NYSE: AMN) delivers technology-enabled workforce solutions to U.S. acute and sub-acute care providers, operating through three distinct segments: Nurse & Allied Solutions, Physician & Leadership Solutions, and Technology & Workforce Solutions. The firm’s portfolio spans travel-nurse and allied-health staffing, crisis-response deployments, locum-tenens physician placements, executive search, language services, vendor-management platforms, and outsourced workforce optimization, under brands such as AMN Healthcare, Nursefinders, and O’Grady Peyton International.
In FY 2023, AMN reported revenue of roughly $5.0 billion, representing a 9 % year-over-year increase driven primarily by higher utilization of travel-nurse and allied-health services. The company’s adjusted EBITDA margin hovered around 7 %, reflecting the capital-light nature of staffing but also the pressure from rising labor-cost inflation. Recent quarterly data show a 12 % YoY growth in travel-nurse billings, while the physician-locum segment posted a 5 % increase, indicating diversified demand across clinical roles.
Key economic and sector drivers include: (1) persistent hospital staffing shortages amplified by the aging U.S. population, which fuels demand for temporary and travel clinicians; (2) the shift toward outpatient and post-acute care settings that expands the market for allied-health professionals such as PTs, RTs, and pharmacists; and (3) macro-level wage inflation in the healthcare labor market, which can both boost AMN’s pricing power and increase its cost base, making margin management a critical focus.
For a deeper, data-driven assessment of AMN’s valuation and risk profile, you may find the analytics on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -275.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 6.28 > 1.0 |
| NWC/Revenue: 1.04% < 20% (prev 3.06%; Δ -2.02% < -1%) |
| CFO/TA 0.12 > 3% & CFO 266.7m > Net Income -275.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (38.7m) vs 12m ago 1.06% < -2% |
| Gross Margin: 27.99% > 18% (prev 0.27%; Δ 2772 % > 0.5%) |
| Asset Turnover: 113.0% > 50% (prev 115.0%; Δ -1.93% > 0%) |
| Interest Coverage Ratio: -4.72 > 6 (EBITDA TTM -105.3m / Interest Expense TTM 56.4m) |
Altman Z'' 2.05
| A: 0.01 (Total Current Assets 570.3m - Total Current Liabilities 542.2m) / Total Assets 2.14b |
| B: 0.57 (Retained Earnings 1.22b / Total Assets 2.14b) |
| C: -0.11 (EBIT TTM -266.1m / Avg Total Assets 2.40b) |
| D: 0.81 (Book Value of Equity 1.22b / Total Liabilities 1.49b) |
| Altman-Z'' Score: 2.05 = BBB |
Beneish M -3.47
| DSRI: 0.95 (Receivables 442.7m/528.6m, Revenue 2.72b/3.07b) |
| GMI: 0.97 (GM 27.99% / 27.20%) |
| AQI: 0.95 (AQ_t 0.65 / AQ_t-1 0.68) |
| SGI: 0.89 (Revenue 2.72b / 3.07b) |
| TATA: -0.25 (NI -275.5m - CFO 266.7m) / TA 2.14b) |
| Beneish M-Score: -3.47 (Cap -4..+1) = AA |
What is the price of AMN shares?
Over the past week, the price has changed by -4.69%, over one month by +29.30%, over three months by +10.15% and over the past year by -22.16%.
Is AMN a buy, sell or hold?
- StrongBuy: 1
- Buy: 2
- Hold: 5
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the AMN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 20.9 | 2.8% |
| Analysts Target Price | 20.9 | 2.8% |
| ValueRay Target Price | 14.3 | -29.5% |
AMN Fundamental Data Overview February 03, 2026
P/S = 0.3012
P/B = 1.2035
P/EG = 1.7113
Revenue TTM = 2.72b USD
EBIT TTM = -266.1m USD
EBITDA TTM = -105.3m USD
Long Term Debt = 846.8m USD (from longTermDebt, last quarter)
Short Term Debt = 6.14m USD (from shortTermDebt, last quarter)
Debt = 884.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 832.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.65b USD (818.2m + Debt 884.9m - CCE 52.6m)
Interest Coverage Ratio = -4.72 (Ebit TTM -266.1m / Interest Expense TTM 56.4m)
EV/FCF = 7.41x (Enterprise Value 1.65b / FCF TTM 222.8m)
FCF Yield = 13.50% (FCF TTM 222.8m / Enterprise Value 1.65b)
FCF Margin = 8.20% (FCF TTM 222.8m / Revenue TTM 2.72b)
Net Margin = -10.14% (Net Income TTM -275.5m / Revenue TTM 2.72b)
Gross Margin = 27.99% ((Revenue TTM 2.72b - Cost of Revenue TTM 1.96b) / Revenue TTM)
Gross Margin QoQ = 23.17% (prev 29.84%)
Tobins Q-Ratio = 0.77 (Enterprise Value 1.65b / Total Assets 2.14b)
Interest Expense / Debt = 1.09% (Interest Expense 9.63m / Debt 884.9m)
Taxrate = 22.91% (8.70m / 38.0m)
NOPAT = -205.2m (EBIT -266.1m * (1 - 22.91%)) [loss with tax shield]
Current Ratio = 1.05 (Total Current Assets 570.3m / Total Current Liabilities 542.2m)
Debt / Equity = 1.37 (Debt 884.9m / totalStockholderEquity, last quarter 644.4m)
Debt / EBITDA = -7.90 (negative EBITDA) (Net Debt 832.3m / EBITDA -105.3m)
Debt / FCF = 3.74 (Net Debt 832.3m / FCF TTM 222.8m)
Total Stockholder Equity = 668.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -11.46% (Net Income -275.5m / Total Assets 2.14b)
RoE = -41.22% (Net Income TTM -275.5m / Total Stockholder Equity 668.4m)
RoCE = -17.57% (EBIT -266.1m / Capital Employed (Equity 668.4m + L.T.Debt 846.8m))
RoIC = -12.65% (negative operating profit) (NOPAT -205.2m / Invested Capital 1.62b)
WACC = 4.78% (E(818.2m)/V(1.70b) * Re(9.04%) + D(884.9m)/V(1.70b) * Rd(1.09%) * (1-Tc(0.23)))
Discount Rate = 9.04% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.69%
[DCF Debug] Terminal Value 84.79% ; FCFF base≈177.8m ; Y1≈154.2m ; Y5≈122.9m
Fair Price DCF = 75.53 (EV 3.73b - Net Debt 832.3m = Equity 2.90b / Shares 38.4m; r=5.90% [WACC]; 5y FCF grow -16.15% → 2.90% )
EPS Correlation: -98.33 | EPS CAGR: -60.10% | SUE: -1.91 | # QB: 0
Revenue Correlation: -97.05 | Revenue CAGR: -18.45% | SUE: 1.20 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.08 | Chg30d=-0.007 | Revisions Net=-2 | Analysts=8
EPS next Year (2026-12-31): EPS=0.68 | Chg30d=-0.033 | Revisions Net=-2 | Growth EPS=-52.0% | Growth Revenue=-5.6%